Phase 2a win and fresh $200M gives bempikibart a clear run at registration — but a single-arm, open-label dataset must hold up in a controlled pivotal trial

Q32 Bio is a clinical-stage company developing bempikibart, a targeted therapy for alopecia areata, which is not yet approved.

Bempikibart, an anti-IL-7R antibody blocking T-cell-driven hair follicle destruction in alopecia areata, met its primary endpoint with a 35.3% SALT score reduction and 40% SALT-20 response rate in a 33-patient open-label Phase 2a. The thesis resolves on whether a registration-directed randomized trial replicates this magnitude of benefit against a placebo-controlled standard. The central risk is that open-label Part B data, generated without a concurrent control arm, may overestimate effect size relative to what a pivotal trial requires.